Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation

• Published in: The Journal of surgical research Vol. 291; pp. 176 - 186
• Main Authors: Kauke-Navarro, Martin, Noel, Olivier F., Knoedler, Leonard, Knoedler, Samuel, Panayi, Adriana C., Stoegner, Viola A., Huelsboemer, Lioba, Pomahac, Bohdan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2023
• Subjects: CRISPR/Cas9; Genetic engineering; Genomic editing; Rejection; Tolerance induction; Vascularized composite allotransplantation; Rejection; Genomic editing; Genetic engineering; CRISPR/Cas9; Tolerance induction; Vascularized composite allotransplantation
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1016/j.jss.2023.04.028

Despite the clinical success in vascularized composite allotransplantation (VCA), systemic immunosuppression remains necessary to prevent allograft rejection. Even with potent immunosuppressive regimens (tacrolimus, mycophenolate mofetil, and steroids), most patients experience several rejection episodes, often within the same year. The risk of systemic side effects must constantly be weighed against the risk of under-immunosuppression and, thus, acute and chronic rejection. In this context, genomic editing has emerged as a potential tool to minimize the need for toxic immunosuppressive regimens and has gained attention in the fields of solid organ transplantation and xenotransplantation. This strategy may also be relevant for the future of VCA. We discuss the topic of genetic engineering and review recent developments in this field that justify investigating tools such as clustered regularly interspaced short palindromic repeats/Cas9 in the context of VCA. We propose specific strategies for VCA based on the most recent gene expression data. This includes the well-known strategy of tolerance induction. Specifically, targeting the interaction between antigen-presenting cells and recipient-derived T cells by CD40 knockout may be effective. The novelty for VCA is a discovery that donor-derived T lymphocytes may play a special role in allograft rejection of facial transplants. We suggest targeting these cells prior to transplantation (e.g., by ex vivo perfusion of the transplant) by knocking out genes necessary for the long-term persistence of donor-derived immune cells in the allograft. Despite the demonstrated feasibility of VCA in recent years, continued improvements to immunomodulatory strategies using tools like clustered regularly interspaced short palindromic repeats/Cas9 could lead to the development of approaches that mitigate the limitations associated with rejection of this life-giving procedure.